ANTXAN2 Therapeutics Inc
$4.83
$0.17
(3.40%)
Reported EarningsMay 11
Mkt Cap$180.08M
Vol485.00
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) PR Newswire NEW YORK, July 20, 2026 NEW YORK, July 20, 2026...
PR Newswire
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Companys oral CPSF3 inhibitor, AN2-502998, for the treatment of...
Business Wire
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June...
Business Wire
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026. This was an...
Business Wire
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...
Business Wire
Anthem (NASDAQ:ANTX) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded Anthem from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat
Anthem (NASDAQ:ANTX) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Anthem from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Anthem (NASDAQ:ANTX) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Anthem to a "hold" rating in a report on Saturday...
MarketBeat
Anthem (NASDAQ:ANTX) Stock Price Up 1.2% - Still a Buy?
Anthem (NASDAQ:ANTX) Shares Up 1.2% - Still a Buy...
MarketBeat
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest ANTX News
ViewSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
PR Newswire
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Business Wire
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Business Wire
Advertisement|Remove ads.